Qsymia, a combination of phentermine and topiramate, has been approved by the FDA for chronic weight management.
- TRADE NAMES: Adipex-P (Teva); Behapront; Diminex; Ionamin (Celltech); Lomaira (Avanthi); Minobese-Forte; Panbesy; Panbesyl; Qsymia (Vivus); Redusa; Suprenza; Umine; Zantryl
- INDICATIONS:
Obesity.
Adjunct for the treatment of obesity and for weight loss management in defined populations and health conditions.
- CLASS: Amphetamine, Anti-obesity / weight loss pharmacotherapy
- HALF-LIFE: 19–24 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Fluoxetine, Fluvoxamine, MAO inhibitors, Paroxetine Hydrochloride, Phenelzine, Sertraline, Tranylcypromine
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 06/28/2025
